glp 1 novo With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins Novo Nordisk testing its blockbuster

CONFIDENCE, COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a UACR Endpoint (NCT05254002)

The use of lixisenatide was associated with up to 2 kg additional weight loss over 12 weeks compared with control in the GetGoal-Mono study [32]

However, not all patients respond effectively to GLP-1R monoagonists, and higher doses aimed at increasing efficacy result in adverse gastrointestinal effects

"We also have a responsibility, as stewards of our members' and customers' premiums, to ensure that the drugs we pay for benefit our members without adding excessive costs that impact all members and customer groups